Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3971 - Array based profiling of emerging molecules in colorectal cancer

Date

09 Sep 2017

Session

Poster display session

Presenters

Eiji Shinozaki

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

E. Shinozaki1, S. Sakata2, T. Konishi3, H. Osumi1, M. Ueno3, K. Yamaguchi1, K. Takeuchi2

Author affiliations

  • 1 Gastrointestinal Oncology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 2 Pathology Project For Molecular Targets, The Cancer Institute of JFCR, 135-8550 - Tokyo/JP
  • 3 Gastroenterological Surgery, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
More

Resources

Abstract 3971

Background

Colorectal cancer (CRC) also has various genetic backgrounds and diversity. In addition to the RAS gene, a lot of new knowledge about molecules playing an important role in the process of carcinogenesis or drug resistance, and emerging molecules as targets for new treatments have been reported recently. In this research, we aim to clarify correlation between emerging molecules and differences through clinical stages in CRC usig tissue array.

Methods

Consecutive patients who underwent sugery in our hospital from June 2003 to March 2011 were enrolled in this study. Tissue array based profiling of emerging molecules was performed on archival samples using immunohistochemistry for MLH1/MSH2/MSH6/PMS2, CDX2, HER2 and PD-L1, and fluorescence in situ hybridization for ERBB2. We analyzed the correlation among molecular profile, overall survival, pathological findings and location of CRC.

Results

A total of 1122 CRC from stage 0 to IV were analyzed; details in Table. In dMMR population, the proportion of PD-L1 expression (19.2%) was increased significantly compared to those in pMMR population (2.5%). In the univariate analysis, CDX2 negative, BRAF mutation and poorly differentiated histology and in the multivariate analysis, CDX2 negative, dMMR and poorly differentiated histology were idnetified as predictive factors for OS in whole population.Table:

570P

All patients (n = 1122)
Median age (±SD)65±11.5
Sex, n (%)
−Male586(52.2)
−Female536(47.8)
Stage of disease at time of presentation, n (%)
−026(2.3)
−I215(19.1)
−II318(28.3)
−III348(30.9)
−IV212(18.8)
−Unknown3(0.2)
Pathology of primary tumor, n (%)
−differentiated1024(91.4)
−poorly differentiated86(7.6)
−unknown13(1.1)
Site of primary tumor, n (%)
−Right sided346(30.8)
−Left sided757(7.6)
−Unknown22(1.9)
Molecular status, n (%)
−dMMR78(6.9)
−CDX2 negative43(3.8)
−BRAF V600E mutation by IHC35(3.1)
−HER2 3+34(3.0)
−ERBB2 amplification26(2.2)
−HER2 3+ and ERBB2 amplification23(2.0)
−PD-L1 positive41(3.6)

Conclusions

Our data comprehensively summarized the significance of the recent emerging molecules in CRC over the clinical stages. These are considered to contribute to precision medicince in near future.

Clinical trial identification

Legal entity responsible for the study

Ethical Guidelines for Medical Research on Humans

Funding

None

Disclosure

E. Shinozaki: Honoraria from Taiho, Merck Serono, Chugai, Yakult, Ono, Takeda, Bayer and Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.